[Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
Gallwitz
B
B
Medizinische Klinik IV, Universitätsklinikum Tübingen. baptist.gallwitz@med.uni-tuebingen.de
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005858:Germany; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
D054873:Dipeptidyl-Peptidase IV Inhibitors; D015507:Drugs, Investigational; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4